Objective: Previously, we retrospectively reported the prevalence and risks of motor and non-motor symptoms of a large number of patients (1453) with Parkinson’s disease (PD) (Parkinsonism Related Disord 2013:19:725-731). We evaluate the prevalence of symptoms and longitudinal changes of treatments in the 7.5 years following the study.

Background: The prospective non-interventional study combined a lot of symptoms with a large number of patients, and it would be useful and important.

Methods: Prevalence and onset of wearing-off, camptocormia, pain, psychosis, pneumonia, malignant syndrome, death, and so on, and the proportion of levodopa, dopamine agonist, non-dopaminergic drugs, deep brain stimulation, levodopa-carbidopa intestinal gel, and electroconvulsive therapy were evaluated.

Results: Over 70% of the patients experienced wearing-off, and logistic regression analysis revealed significantly higher Odds ratios for females, older age, younger age onset, daily dose of levodopa, and the time period to start of levodopa. 40% of the patients experienced psychosis mainly, hallucination, significant high Odds ratios were older age, younger age onset, and Hoehn and Yahr stage (H & Y). Some patients who were previously enrolled, changed the hospital due to feasibility of the hospital, while others were lost in this way. One hundred-thirty-three patients (female 70, onset age 61.0 (11.9) mean (SD), age at the time of death 74.5 (8.1) years old, H & Y 4.1 (0.8), daily levodopa dose 718.6 (251.1) mg) died with the disease progression including aspiration pneumonia (63 patients), malignant tumor (11), other diseases (32), or unknown causes (27). The 445 patients who have been followed until now and evaluated are 69.8 (10.5) years old, their onset age was 54.9 (12.3), H & Y 3.3 (1.1), daily levodopa dose 619.6 (259.0) mg.

Conclusions: We will show the contents change of the of drug construction, and the increased prevalence of events or risks. Various symptoms and complications in large cohort of patients might be determined by age or sex.

References: Yoritaka A, Shimo Y, Takanashi M, Fukae J, Hatano T, Nakahara T, Miyamato N, Urabe T Mori H, Hattori N. Motor and non-motor symptoms of 1453 patients with Parkinson’s disease: Prevalence and risks. Parkinsonism & Related Disord 2013;19:725-731.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/motor-and-non-motor-symptoms-of-a-7-5-year-prospective-study-of-patients-with-parkinsons-disease/